# Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine

## TL;DR

This study explores a pan-RAS mRNA vaccine for pancreatic cancer, focusing on its immunogenic potential and structural stability for clinical use.

## Contribution

The study evaluates a specific mRNA vaccine construct for targeting multiple KRAS mutations in pancreatic cancer using immunoinformatics.

## Key findings

- The vaccine construct showed favorable antigenicity, stability, and non-toxic profiles.
- Molecular simulations indicated stable interactions with TLR7/8 but no direct R848 binding.
- Codon optimization and immune simulations predicted strong immunogenic potential.

## Abstract

KRAS mutations, particularly at codon 12, occur in over 90% of pancreatic ductal adenocarcinoma (PDAC) cases and drive tumor initiation, progression, and therapeutic resistance. Targeting oncogenic KRAS variants through immunotherapy offers a promising strategy for PDAC treatment. This study evaluated Seq ID No. 70 of a pan-RAS mRNA cancer vaccine (WO 2022/081764 A1; PCT/US 2021/054859), incorporating KRAS variants G12D, G13D, L19F, A59T, G60D, Q61H, K117N, and A146T, for its suitability in PDAC.

Immunoinformatic analyses were performed to predict cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B-cell epitopes, which were assessed for antigenicity, allergenicity, and toxicity. Physicochemical profiling, secondary structure prediction, and 3D structural modeling with refinement were conducted. Molecular docking and 500 ns molecular dynamics simulations evaluated interactions with Toll-like receptors TLR7/8 and the agonist resiquimod (R848). Solvent-accessible surface area (SASA) analysis examined epitope exposure. Codon optimization assessed expression efficiency, and immune simulations predicted immunogenicity.

Multiple epitopes demonstrated favorable antigenicity with non-allergenic and non-toxic profiles. The construct was predicted to be stable, hydrophilic, and structurally refined. Docking and MD simulations showed stable interactions with TLR7/8; no direct R848–vaccine binding was observed. SASA analysis indicated strong solvent exposure, supporting immunogenic potential. Codon optimization yielded favorable parameters (CAI = 0.956; GC = 61.7%) and a molecular weight of 21,973.98 Da. Immune simulations predicted robust cellular and humoral responses.

The pan-RAS mRNA vaccine demonstrates structural stability and strong immunogenic potential for PDAC. Synergistic immune activation with R848 may enhance anti-tumor efficacy, warranting experimental validation and toxicity assessment for clinical translation.